SG11202105776WA - Imidazo[1,2-b]pyridazine il-17a inhibitors - Google Patents

Imidazo[1,2-b]pyridazine il-17a inhibitors

Info

Publication number
SG11202105776WA
SG11202105776WA SG11202105776WA SG11202105776WA SG11202105776WA SG 11202105776W A SG11202105776W A SG 11202105776WA SG 11202105776W A SG11202105776W A SG 11202105776WA SG 11202105776W A SG11202105776W A SG 11202105776WA SG 11202105776W A SG11202105776W A SG 11202105776WA
Authority
SG
Singapore
Prior art keywords
imidazo
pyridazine
inhibitors
Prior art date
Application number
SG11202105776WA
Other languages
English (en)
Inventor
David Andrew Coates
Kwame Frimpong
William Glen Holloway
Spencer Brian Jones
Adam Marc Levinson
Charles Willis Lugar Iii
Michael Enrico Richett
Brian Morgan Watson
Michael Edward Woodman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202105776WA publication Critical patent/SG11202105776WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SG11202105776WA 2019-01-07 2020-01-03 Imidazo[1,2-b]pyridazine il-17a inhibitors SG11202105776WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789247P 2019-01-07 2019-01-07
US201962842770P 2019-05-03 2019-05-03
PCT/US2020/012115 WO2020146194A1 (en) 2019-01-07 2020-01-03 Imidazo[1,2-b]pyridazine il-17a inhibitors

Publications (1)

Publication Number Publication Date
SG11202105776WA true SG11202105776WA (en) 2021-06-29

Family

ID=69423406

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105776WA SG11202105776WA (en) 2019-01-07 2020-01-03 Imidazo[1,2-b]pyridazine il-17a inhibitors

Country Status (23)

Country Link
US (1) US20220073526A1 (zh)
EP (1) EP3908585B1 (zh)
JP (1) JP7291226B2 (zh)
KR (1) KR102600451B1 (zh)
CN (1) CN113286795B (zh)
AU (1) AU2020207196B2 (zh)
BR (1) BR112021011095B1 (zh)
CA (1) CA3125788C (zh)
CL (1) CL2021001720A1 (zh)
CO (1) CO2021008776A2 (zh)
CR (1) CR20210357A (zh)
DO (1) DOP2021000132A (zh)
EC (1) ECSP21050201A (zh)
ES (1) ES2977743T3 (zh)
IL (1) IL284228B2 (zh)
JO (1) JOP20210179A1 (zh)
MA (1) MA54696A (zh)
MX (1) MX2021008176A (zh)
PE (1) PE20212304A1 (zh)
SA (1) SA521422452B1 (zh)
SG (1) SG11202105776WA (zh)
TW (2) TW202214648A (zh)
WO (1) WO2020146194A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
BR112022021962A2 (pt) 2020-04-30 2023-03-28 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
IL298887A (en) 2020-06-12 2023-02-01 Leo Pharma As Small molecule modulators of IL-17
WO2021255174A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
WO2021255086A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
WO2021255085A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
EP3943495A1 (en) 2020-07-24 2022-01-26 Leo Pharma A/S Small molecule modulators of il-17
CN113999234B (zh) * 2020-07-28 2023-03-07 成都先导药物开发股份有限公司 一种免疫调节剂
US20230399328A1 (en) 2020-11-09 2023-12-14 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
US20240140951A1 (en) 2020-12-14 2024-05-02 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
AR126255A1 (es) 2021-07-01 2023-10-04 UCB Biopharma SRL Derivados de imidazotriazina como moduladores de il-17
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022348938A1 (en) * 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
CA3233408A1 (en) * 2021-09-27 2023-03-30 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
TW202413363A (zh) * 2021-11-04 2024-04-01 大陸商西藏海思科製藥有限公司 一種可抑制il-17a之雜環化合物及其用途
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
CN114736104B (zh) * 2022-04-20 2024-04-19 上海恩氟佳科技有限公司 一种二氟乙醛缩半乙醇的合成方法
WO2023225664A1 (en) * 2022-05-19 2023-11-23 Dice Alpha, Inc. Lactam substituted imidazopyridazine il-17a modulators and uses thereof
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents
WO2024115662A1 (en) 2022-12-02 2024-06-06 Leo Pharma A/S Small molecule modulators of il-17
WO2024138286A1 (en) * 2022-12-26 2024-07-04 Usynova Pharmaceuticals, Ltd. Il-17a modulators
WO2024163365A1 (en) * 2023-01-30 2024-08-08 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
WO2024173173A1 (en) * 2023-02-13 2024-08-22 Dice Alpha, Inc. Imidazotriazine il-17a modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007104696A1 (en) * 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
JP5313909B2 (ja) * 2006-11-13 2013-10-09 アイコス コーポレイション 炎症性疾患および癌の処置のためのチエノピリミジノン
EP2892899B1 (en) * 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
JP6458038B2 (ja) * 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
KR20180081584A (ko) * 2015-11-18 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물

Also Published As

Publication number Publication date
AU2020207196B2 (en) 2022-03-17
BR112021011095B1 (pt) 2023-11-28
BR112021011095A2 (pt) 2021-08-31
CN113286795B (zh) 2023-11-03
PE20212304A1 (es) 2021-12-10
US20220073526A1 (en) 2022-03-10
WO2020146194A1 (en) 2020-07-16
EP3908585B1 (en) 2024-03-06
DOP2021000132A (es) 2021-07-22
TWI752400B (zh) 2022-01-11
CL2021001720A1 (es) 2022-01-21
TW202039505A (zh) 2020-11-01
ECSP21050201A (es) 2021-08-31
SA521422452B1 (ar) 2023-12-05
EP3908585A1 (en) 2021-11-17
JP2022516654A (ja) 2022-03-01
MX2021008176A (es) 2021-10-13
JOP20210179A1 (ar) 2023-01-30
CA3125788C (en) 2023-10-31
IL284228B2 (en) 2024-05-01
MA54696A (fr) 2022-04-13
KR20210100143A (ko) 2021-08-13
CN113286795A (zh) 2021-08-20
AU2020207196A1 (en) 2021-06-17
JP7291226B2 (ja) 2023-06-14
CR20210357A (es) 2021-09-01
IL284228B1 (en) 2024-01-01
ES2977743T3 (es) 2024-08-29
CA3125788A1 (en) 2020-07-16
IL284228A (en) 2021-08-31
KR102600451B1 (ko) 2023-11-10
TW202214648A (zh) 2022-04-16
CO2021008776A2 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
IL284228A (en) imidazo[1,2-b]pyridazine il-17a inhibitors
ZA201905456B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL276802B1 (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
IL289462A (en) Pyrazolo[4,3-b]pyrozine as shp2 phosphatase inhibitors
IL280513A (en) Imidazo[2,1-B]pyridazines as TRK inhibitors
IL285311A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
EP3956322A4 (en) JAK1 SELECTIVE KINAS INHIBITOR
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
ZA202000875B (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
EP3475286A4 (en) USE OF PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES COMPOUNDS SUBSTITUTED AS INHIBITORS OF PROTEIN KINASES
IL279156A (en) History of hexahydropyrrolo[4,3-C]pyrrole useful as LOX inhibitors